He Y, Xu B, Zhang M, Chen D, Wu S, Gao J
J Headache Pain. 2025; 26(1):46.
PMID: 40016636
PMC: 11869436.
DOI: 10.1186/s10194-025-01979-4.
Krivoshein G, Rivera-Mancilla E, MaassenVanDenBrink A, Giniatullin R, van den Maagdenberg A
J Headache Pain. 2025; 26(1):40.
PMID: 39994546
PMC: 11853570.
DOI: 10.1186/s10194-025-01966-9.
Ayoub M, Chela H, Amin N, Hunter R, Anwar J, Tahan V
J Clin Med. 2025; 14(3).
PMID: 39941615
PMC: 11818918.
DOI: 10.3390/jcm14030944.
Al-Noshokaty T, Abdelhamid R, Abdelmaksoud N, Khaled A, Hossam M, Ahmed R
Toxicol Rep. 2025; 14:101895.
PMID: 39911322
PMC: 11795145.
DOI: 10.1016/j.toxrep.2025.101895.
Duran M, Willis J, Dalvi N, Fokakis Z, Virkus S, Hardaway J
Endocrinology. 2025; 166(3).
PMID: 39888375
PMC: 11850305.
DOI: 10.1210/endocr/bqaf019.
Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification.
Gomaa M, Alturki M, Tawfeeq N, Hussein D, Pottoo F, Al Khzem A
Pharmaceutics. 2025; 16(12.
PMID: 39771585
PMC: 11679513.
DOI: 10.3390/pharmaceutics16121607.
Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.
Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S
Front Cardiovasc Med. 2025; 11:1446468.
PMID: 39741663
PMC: 11685754.
DOI: 10.3389/fcvm.2024.1446468.
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration.
Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y
Pharmaceutics. 2024; 16(11).
PMID: 39598478
PMC: 11597531.
DOI: 10.3390/pharmaceutics16111353.
A Cross-Sectional Study: Systematic Quantification of Chemerin in Human Cerebrospinal Fluid.
Hopfinger A, Behrendt M, Schmid A, Karrasch T, Schaffler A, Berghoff M
Biomedicines. 2024; 12(11).
PMID: 39595074
PMC: 11592017.
DOI: 10.3390/biomedicines12112508.
Impact of glucagon-Like peptide-1 agonists in optimizing abdominal wall Reconstruction patients.
Tran D, Farias D, Tanner M, Marroquin M, Jefferies R, Ogola G
Hernia. 2024; 29(1):19.
PMID: 39549167
DOI: 10.1007/s10029-024-03214-6.
Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.
Rico-Fontalvo J, Reina M, Soler M, Unigarro-Palacios M, Castaneda-Gonzalez J, Quintero J
J Bras Nefrol. 2024; 46(4):e20240101.
PMID: 39514688
PMC: 11548866.
DOI: 10.1590/2175-8239-JBN-2024-0101en.
Glucose metabolism impairment as a hallmark of progressive myoclonus epilepsies: a focus on neuronal ceroid lipofuscinoses.
Santucci L, Bernardi S, Vivarelli R, Santorelli F, Marchese M
Front Cell Neurosci. 2024; 18:1445003.
PMID: 39364042
PMC: 11447523.
DOI: 10.3389/fncel.2024.1445003.
Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.
Caturano A, Vetrano E, Galiero R, Sardu C, Rinaldi L, Russo V
Int J Mol Sci. 2024; 25(18).
PMID: 39337658
PMC: 11432093.
DOI: 10.3390/ijms251810173.
The nucleus accumbens shell: a neural hub at the interface of homeostatic and hedonic feeding.
Marinescu A, Labouesse M
Front Neurosci. 2024; 18:1437210.
PMID: 39139500
PMC: 11319282.
DOI: 10.3389/fnins.2024.1437210.
Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review.
Halloum W, Dughem Y, Beier D, Pellesi L
J Headache Pain. 2024; 25(1):112.
PMID: 38997662
PMC: 11241973.
DOI: 10.1186/s10194-024-01821-3.
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review.
Sinclair S, Miller E, Talekar K, Schwartz S
Front Ophthalmol (Lausanne). 2024; 2:1012804.
PMID: 38983558
PMC: 11182219.
DOI: 10.3389/fopht.2022.1012804.
KEAP1 overexpression is correlated with poor prognosis and immune infiltration in liver hepatocellular carcinoma.
Wei X, Tang Y, Zheng M, Xu Y, Wang Z
Front Med (Lausanne). 2024; 11:1391843.
PMID: 38938386
PMC: 11208630.
DOI: 10.3389/fmed.2024.1391843.
Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.
Abiola J, Oluyemi A, Idowu O, Oyinloye O, Ubah C, Owolabi O
Pharmaceuticals (Basel). 2024; 17(6).
PMID: 38931402
PMC: 11206448.
DOI: 10.3390/ph17060736.
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review.
Nikolaidou A, Ventoulis I, Karakoulidis G, Anastasiou V, Daios S, Papadopoulos S
Medicina (Kaunas). 2024; 60(6).
PMID: 38929529
PMC: 11205945.
DOI: 10.3390/medicina60060912.
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.
Tamayo-Trujillo R, Ruiz-Pozo V, Cadena-Ullauri S, Guevara-Ramirez P, Paz-Cruz E, Zambrano-Villacres R
Front Nutr. 2024; 11:1398059.
PMID: 38742021
PMC: 11090168.
DOI: 10.3389/fnut.2024.1398059.